Crescita Therapeutics (TSX:CTX) Inventories, Finished Goods: C$2.57 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:CTX Crescita Therapeutics Inc TSX:CTX
20 GF Score
Price C$0.79
GF Value C$0.68
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Crescita Therapeutics Inventories, Finished Goods?

Crescita Therapeutics TSX:CTX 20 Inventories, Finished Goods is C$2.57 Mil as of Mar. 2026. GuruFocus rates TSX:CTX with a GF Score™ of 20/100 and a GF Value™ of C$0.68 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Crescita Therapeutics's quarterly finished goods declined from Sep. 2025 (C$3.22 Mil) to Dec. 2025 (C$2.84 Mil) and declined from Dec. 2025 (C$2.84 Mil) to Mar. 2026 (C$2.57 Mil).

Crescita Therapeutics's annual finished goods declined from Dec. 2023 (C$3.04 Mil) to Dec. 2024 (C$2.50 Mil) but then increased from Dec. 2024 (C$2.50 Mil) to Dec. 2025 (C$2.84 Mil).

Crescita Therapeutics Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Crescita Therapeutics's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crescita Therapeutics Inventories, Finished Goods Chart

Crescita Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.19 2.20 3.04 2.50 2.84

Crescita Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.07 2.49 3.22 2.84 2.57
TSX:CTX
20GF Score
Crescita Therapeutics Inc TSX:CTX
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crescita Therapeutics Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of C$2.57 Mil mean?
Crescita Therapeutics (TSX:CTX) has a Inventories, Finished Goods of C$2.57 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on Crescita Therapeutics and its competitors.
Is Crescita Therapeutics' Inventories, Finished Goods too high?
Crescita Therapeutics' current Inventories, Finished Goods is C$2.57 Mil. Overall, Crescita Therapeutics has a GF Score™ of 20/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Crescita Therapeutics' Inventories, Finished Goods compare to ZTS?
Crescita Therapeutics' Inventories, Finished Goods of C$2.57 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Drug Manufacturers company?
A good Inventories, Finished Goods depends on the Drug Manufacturers industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Crescita Therapeutics and its competitors. Crescita Therapeutics's current Inventories, Finished Goods is C$2.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescita Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Crescita Therapeutics (TSX:CTX) is currently considered Modestly Overvalued. The stock's GF Value™ is C$0.68, compared to a current price of C$0.79 — trading 16.2% above its estimated fair value. The current Inventories, Finished Goods is C$2.57 Mil. Crescita Therapeutics' overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Crescita Therapeutics (TSX:CTX), the current Inventories, Finished Goods is C$2.57 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Crescita Therapeutics (TSX:CTX) Overvalued in 2026?

Based on GuruFocus' analysis, Crescita Therapeutics stock appears to be overvalued. The current stock price of C$0.79 is trading 16.2% above its estimated GF Value™ of C$0.68. GuruFocus considers Crescita Therapeutics to be Modestly Overvalued.

Key valuation signals for TSX:CTX:

  • Inventories, Finished Goods: C$2.57 Mil
  • GF Value™: C$0.68 vs. price of C$0.79 (16.2% above fair value)
  • GF Score™: 20/100 with 5 warning signs

No single metric tells the full story. See the TSX:CTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Crescita Therapeutics Business Description

Address 2805, Place Louis-R-Renaud, Laval, QC, CAN, H7V 0A3
Crescita Therapeutics Inc is a commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue from Commercial Skincare Product Sales in Canada followed by USA and Rest of the world.
20GF Score

Get the complete analysis for TSX:CTX

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.79
Price
C$0.68
GF Value